Skip to main content
Caplight Logo









Genome

Genome

Private
VilniusFinTechhttps://genome.eu

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Genome operates in FinTech and is based in Vilnius. It was founded in 2018.

Genome is a fintech company that provides an all-in-one financial ecosystem offering personal and business IBAN accounts, payment processing, and currency exchange services.

Sector

FinTech

Verticals

Digital Banking, Digital Payments, Corporate Banking, Foreign Exchange, Personal Finance

Business Model

B2B

Customer Profile

Usage-Based SaaS, Subscription SaaS

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Genome Comparables

Compare Genome with similar companies based on industry and business-model similarity.

Genome comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VIALET
88%
3S Money
78%
Juni
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Genome Funding Rounds

Historical fundraising activity

Funding history

No completed funding rounds are published for Genome. Book a demo to ask about coverage.

Book a demo

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Daumantas Barauskas

CEO, Board Member

Executive Team

Yuriy Rudenko

Chief Technology Officer

Executive Team

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 2, 2026

    Open roles increased to 47, 33% of headcount.

  • Aug 31, 2026

    Open roles increased to 17, 2.1x the trailing average.

Book a demo to see all signals

For institutional investors. Book with your work email.

Genome Filings

Explore SEC and related filing metadata, where available.

Genome filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Genome's valuation, stock price, and market status.

Is Genome a public or private company?

Genome is a private company.

What is the current stock price of Genome?

Genome is a private company, so its shares have no public market price. Caplight tracks Genome's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Genome worth (valuation)?

Valuation information for Genome is not publicly available.

Can I buy Genome stock?

Genome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Genome's last funding round?

Funding round information for Genome is not publicly available.

Who are the main investors in Genome?

Investor information for Genome is not publicly disclosed.

Will Genome IPO soon?

No public IPO plans have been announced for Genome.

How can I track Genome secondary market activity?

Caplight tracks bids, offers, and trades in Genome's shares on secondary markets.

Firmographic Details

HeadquartersVilnius
Employee Range114
Year Founded2018
Last Funding—

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?